Valuation: Ind-Swift Laboratories Limited

Market Cap 29.3B 312M 280M 256M 233M 439M 453M 3.08B 1.23B 15.63B 1.17B 1.14B 49.36B P/E 2025
2.38x
P/E 2026 26.1x
Enterprise Value 25.09B 267M 239M 219M 200M 376M 388M 2.64B 1.05B 13.39B 1B 980M 42.26B EV / Sales 2025
0.12x
EV / Sales 2026 1.11x
Free-Float
32.35%
Yield 2025 *
-
Yield 2026 -
1 day+0.24%
1 week-1.19%
Current month-5.20%
1 month-3.28%
3 months+47.13%
6 months+151.95%
Current year+295.97%
1 week 331.85
Extreme 331.85
382
1 month 316
Extreme 316
426.6
Current year 87.25
Extreme 87.25
426.6
1 year 87.15
Extreme 87.15
426.6
3 years 68.72
Extreme 68.72
426.6
5 years 52.65
Extreme 52.65
426.6
10 years 15
Extreme 15
426.6
Manager TitleAgeSince
Chief Executive Officer 46 -
Chief Executive Officer 44 2011-06-14
Director of Finance/CFO - 2018-09-28
Director TitleAgeSince
Director/Board Member 44 -
Chairman 74 -
Director/Board Member 35 2010-03-22
Date Insider Type Main position Quantity % Market Cap. Importance
9/12/24 Sell

Chief Financial Officer

30,000 0.0508%
Change 5-day change 1-year change 3-year change Capi.($)
+0.24%-1.19%+234.95%+268.78% 312M
-0.79%-4.48%+46.48%+118.69% 1,206B
+1.43%+1.11%+48.05%+83.72% 665B
+1.07%-1.21%+32.92%+105.10% 515B
+1.58%-0.18%+42.17%+66.53% 381B
-0.14%-1.87%+70.06%+40.55% 362B
+1.05%+2.22%+31.55%+59.48% 307B
+1.45%+1.99%+7.69%+35.45% 289B
+0.03%-1.20%+43.79%+68.49% 249B
-0.41%-2.22%+40.43%+114.24% 207B
Average +0.55%-1.93%+59.81%+96.10% 418.01B
Weighted average by Cap. +0.42%-1.96%+42.49%+86.65%

Financials

2025 2026
Net sales 5.62B 59.76M 53.59M 48.98M 44.71M 84.24M 86.9M 590M 235M 3B 224M 219M 9.46B 6.49B 69.06M 61.94M 56.6M 51.67M 97.35M 100M 682M 272M 3.46B 259M 254M 10.93B
Net income 2.5B 26.65M 23.9M 21.84M 19.94M 37.56M 38.75M 263M 105M 1.34B 100M 97.87M 4.22B 431M 4.59M 4.11M 3.76M 3.43M 6.47M 6.67M 45.33M 18.07M 230M 17.22M 16.85M 726M
Net Debt -4.27B -45.38M -40.7M -37.19M -33.95M -63.97M -65.99M -448M -179M -2.28B -170M -167M -7.19B -4.21B -44.81M -40.19M -36.73M -33.53M -63.18M -65.17M -443M -177M -2.25B -168M -165M -7.1B
Projected Income Statement - Annual - Ind-Swift Laboratories Limited
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,388
Date Price Change Volume
26-11-09 ₹349.05 +0.24% 518,533
26-11-08 ₹336.95 -3.23% 217,438
26-11-06 ₹348.20 -2.40% 354,791
26-11-05 ₹356.75 -3.72% 738,129
26-11-04 ₹370.55 +7.80% 685,300
  1. Stock Market
  2. Stocks
  3. INDSWFTLAB Stock